Xuesong Yang

Xuesong Yang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LSLiang Su
Liang Su
CXChunyan Xu
Chunyan Xu
HHHong Huang
Hong Huang
PZPeilian Zhang
Peilian Zhang
JWJinrong Wang
Jinrong Wang
JYJianzhou Ye
Jianzhou Ye
Background: There is no consensus on the effect of tumor necrosis factor-alpha (TNF-alpha) inhibitors on lipid profiles in patients with psoriasis. This study aimed to investigate the effects of TNF-alpha inhibitors on lipid profiles (triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein) in patients with psoriasis. Methods: We searched PubMed, Embase, and Cochrane Library databases for articles published before October 17, 2023. Four TNF-alpha inhibitors (infliximab, etanercept, adalimumab, and certolizumab) were included in our study. (PROSPERO ID: CRD42023469703).Results: A total of twenty trials were included. Overall results revealed that TNF-alpha inhibitors elevated high-density lipoprotein levels in patients with psoriasis (WMD = 2.31; 95% CI: 0.96, 3.67; P = 0.001), which was supported by the results of sensitivity analyses excluding the effect of lipid-lowering drugs. Subgroup analyses indicated that high-density lipoprotein levels were significantly increased in the less than or equal to 3 months group (WMD = 2.88; 95% CI: 1.37, 4.4; P < 0.001), the etanercept group (WMD = 3.4; 95% CI = 1.71, 5.09, P < 0.001), and the psoriasis group (WMD = 2.52; 95% CI = 0.57, 4.48, P = 0.011). Triglyceride levels were significantly increased in the 3 to 6-month group (WMD = 4.98; 95% CI = 1.97, 7.99, P = 0.001) and significantly decreased in the 6-month and older group (WMD = -19.84; 95% CI = -23.97, -15.7, P < 0.001). Additionally, Triglyceride levels were significantly increased in the psoriasis group (WMD = 5.22; 95% CI = 2.23, 8.21, P = 0.001). Conclusion: Our results revealed that TNF-alpha inhibitors might temporarily increase high-density lipoprotein levels in patients with psoriasis. However, changes in triglycerides were not consistent among the different durations of treatment, with significant increases after 3 to 6 months of treatment. Future prospective trials with long-term follow-up contribute to confirming and extending our findings.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023469703.

15 January 2025 in Computational Biology and Chemistry
Verified
Journal Article
Open access
MZManyin Zhai
Manyin Zhai
TCTongxiu Chen
Tongxiu Chen
MSMengqiu Shao
Mengqiu Shao
XYXuesong Yang
Xuesong Yang
YQYan Qi
Yan Qi
EYEnpin Yang
Enpin Yang
Psoriasis is a common clinical skin inflammatory disease. Haitang-Xiaoyin Mixture (HXM) represents a traditional Chinese medicine formulation utilized clinically for the management of psoriasis, which can reduce the psoriasis area and severity index (PASI) score, IL-23 and IL-23 levels in patients with psoriasis. However, the main active components and specific targets of HXM in the treatment of psoriasis and the relevant mechanisms of action are not clear. Therefore, in the study we aimed to elucidate the mechanistic basis of HXM's therapeutic action in psoriasis treatment through the application of bioinformatics, network pharmacology, machine learning and molecular docking methodologies. The psoriasis-related genes were obtained from the Gene Expression Omnibus (GEO) dataset, which psoriasis-associated disease genes were identified utilizing the GeneCard and DisGeNEt databases. The active ingredients of HXM were retrieved from HERB and TCMSP databases. Protein-Protein Interactions (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to identify potential targets and signaling pathways. Psoriasis key targets were determined using LASSO, SVM-RFE, and Boruta algorithms, followed by Receiver Operating Characteristic (ROC) analysis. Key targets were GESA enriched and analyzed for transcription factors and immune cell infiltration. Finally molecular docking and molecular dynamics simulations were performed to validate the binding of active compounds to core targets, elucidating their mechanism of action. A total of 233 psoriasis-related targets and 290 drug targets were identified. After data set crossover, 37 pharmacodynamic targets were obtained. PPI network topology analysis revealed 12 core targets. GO and KEGG enrichment analysis suggested that HXM may regulate angiogenesis, chemokine receptor binding process, as well as IL-17 and TNF related signaling pathways. Machine algorithm screening identified two psoriasis characteristic genes: CXCL2 and CXCR4. Immune infiltration results demonstrated a significant positive correlation between the characteristic genes and M1 macrophages, along with identification of the top 20 transcription factors involved. Quercetin and triptolide were recognized as potential core components of HXM for treating psoriasis based on their molecular docking and molecular dynamics simulation results confirming strong binding abilities with CXCL2 and CXCR4 respectively. This study elucidates the active constituents, potential targets, and underlying pathways involved in the therapeutic effects of HXM for psoriasis. Specifically, CXCL2 and CXCR4 are identified as key targets, with quercetin and triptolide representing crucial compounds exerting their effects on these targets.

15 March 2024 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
LSLiang Su
Liang Su
FWFang Wang
Fang Wang
YWYuan Wang
Yuan Wang
CQCheng Qin
Cheng Qin
XYXuesong Yang
Xuesong Yang
JYJianzhou Ye
Jianzhou Ye

9 December 2023 in Food Science & Nutrition
Verified
Journal Article
Open access
LSLiang Su
Liang Su
FWFang Wang
Fang Wang
CQCheng Qin
Cheng Qin
ZWZhimin Wang
Zhimin Wang
XYXuesong Yang
Xuesong Yang
JYJianzhou Ye
Jianzhou Ye
The relationship between a pro‐inflammatory diet, assessed by the dietary inflammatory index (DII), and allergic diseases has attracted attention. However, the association between DII and immunoglobulin E (IgE) remains uncertain. We aim to investigate the association between energy‐adjusted DII (E‐DII) and total IgE. We analyzed data from the 2005 to 2006 National Health and Nutrition Examination Survey. The relationship between E‐DII and total IgE was assessed using linear regression and logistic regression analysis. Meanwhile, we conducted a subgroup analysis stratified by body mass index (BMI) and analyzed the mediating role of BMI. We included 3614 adult participants. After controlling for confounding factors, there was no statistical association between E‐DII and total IgE (β 0.023, 95% CI −0.01 to 0.057, p = .173) and the risk of high total IgE (OR 1.036, 95% CI 0.977 to 1.099, p = .233). We conducted subgroup analysis stratified by BMI. After controlling for confounding factors, only in overweight groups, E‐DII was statistically associated with total IgE (β 0.076, 95% CI 0.017 to 0.135, p = .012) and the risk of high total IgE (OR 1.124, 95% CI 1.015 to 1.246, p = .025). Generalized additive models and smooth curve fittings showed a positive linear relationship between E‐DII and total IgE in overweight participants. No statistical association was noted for the mediation effect of BMI on the association between E‐DII and total IgE in the overweight group (p = .23). Overweight participants with higher E‐DII were potentially at risk of elevated total IgE.